CY1117834T1 - Νεα φωσφορικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν - Google Patents

Νεα φωσφορικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν

Info

Publication number
CY1117834T1
CY1117834T1 CY20161100696T CY161100696T CY1117834T1 CY 1117834 T1 CY1117834 T1 CY 1117834T1 CY 20161100696 T CY20161100696 T CY 20161100696T CY 161100696 T CY161100696 T CY 161100696T CY 1117834 T1 CY1117834 T1 CY 1117834T1
Authority
CY
Cyprus
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
opo
new phosphorus
Prior art date
Application number
CY20161100696T
Other languages
English (en)
Inventor
Tiran Arnaud Le
Diguarher Thierry Le
Jérôme-Benoît Starck
Jean-Michel Henlin
Anne-Françoise Guillouzic
Nanteuil Guillaume De
Olivier Geneste
James Edward Paul Davidson
James Brooke Murray
I-Jen Chen
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288170&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117834(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of CY1117834T1 publication Critical patent/CY1117834T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Ενώσεις του τύπου (Ι) στον οποίο τα Χ, Υ, Α1, Α2, Ra, Rb, Rc, Rd, R3, R4, Τ και R5 είναι όπως ορίστηκαν στην περιγραφή. Οι ενώσεις του τύπου (I) είναι τέτοιες ώστε τουλάχιστον ένα από τα άτομα άνθρακα που τις αποτελούν είναι υποκατεστημένο με μια από τις ακόλουθες φωσφορικές ομάδες: - ΟΡΟ(ΟΜ)(ΟΜ'), -ΟΡΟ(ΟΜ)(ΟΜ1+), -ΟΡΟ(Ο-Μ1+)(ΟΜ2+), -ΟΡΟ(O-)(O-)Μ32+, -OPO(OM)(O[CH2CH2O]nCH3), ή -ΟΡΟ(Ο-Μ1+) (Ο[CH2CH2O]nCH3). Ένωση του τύπου (I) για τη χρήση της ως φάρμακο στη θεραπεία των καρκίνων.
CY20161100696T 2013-07-23 2016-07-18 Νεα φωσφορικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν CY1117834T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1357259A FR3008979B1 (fr) 2013-07-23 2013-07-23 Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
CY1117834T1 true CY1117834T1 (el) 2017-05-17

Family

ID=50288170

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100696T CY1117834T1 (el) 2013-07-23 2016-07-18 Νεα φωσφορικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν

Country Status (48)

Country Link
US (3) US9115159B2 (el)
EP (1) EP2829545B1 (el)
JP (1) JP5894638B2 (el)
KR (2) KR101713103B1 (el)
CN (1) CN104341451B (el)
AP (1) AP2014007773A0 (el)
AR (1) AR097008A1 (el)
AU (1) AU2014203808B2 (el)
BR (1) BR102014017997B1 (el)
CA (1) CA2856886C (el)
CL (1) CL2014001865A1 (el)
CR (1) CR20140336A (el)
CU (1) CU24316B1 (el)
CY (1) CY1117834T1 (el)
DK (1) DK2829545T3 (el)
DO (1) DOP2014000163A (el)
EA (1) EA027444B1 (el)
EC (1) ECSP14008757A (el)
ES (1) ES2593417T3 (el)
FR (1) FR3008979B1 (el)
GE (1) GEP201706704B (el)
HK (2) HK1201536A1 (el)
HR (1) HRP20161202T8 (el)
HU (1) HUE029616T2 (el)
IL (1) IL233580B (el)
JO (1) JO3160B1 (el)
MA (1) MA37213B1 (el)
MD (1) MD4551C1 (el)
ME (1) ME02641B (el)
MX (1) MX351467B (el)
MY (1) MY173258A (el)
NI (1) NI201400080A (el)
PE (1) PE20150218A1 (el)
PH (1) PH12014000194B1 (el)
PL (1) PL2829545T3 (el)
PT (1) PT2829545T (el)
RS (1) RS55098B1 (el)
RU (1) RU2617682C2 (el)
SA (1) SA114350669B1 (el)
SG (1) SG10201403939WA (el)
SI (1) SI2829545T1 (el)
SV (1) SV2014004771A (el)
TN (1) TN2014000301A1 (el)
TW (1) TWI527824B (el)
UA (1) UA119738C2 (el)
UY (1) UY35661A (el)
WO (1) WO2015011399A1 (el)
ZA (1) ZA201405418B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
FR3008976A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
FR3008977A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UY37316A (es) * 2016-07-07 2018-01-31 Servier Lab Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer
TWI759316B (zh) * 2016-07-22 2022-04-01 法商施維雅藥廠 Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
GEP20217301B (en) * 2016-07-22 2021-10-11 Servier Lab Combination of bcl-2 inhibitor and mcl-1 inhibitor, uses and pharmaceutical compositions thereof
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
EA039621B1 (ru) * 2017-06-09 2022-02-17 Ле Лаборатуар Сервье Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
WO2019008126A1 (en) * 2017-07-06 2019-01-10 Les Laboratoires Servier NOVEL CRYSTALLINE FORM OF BCL-2 INHIBITOR, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR3072679B1 (fr) * 2017-10-25 2020-10-30 Servier Lab Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN111818915B (zh) 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
AU2020329956B2 (en) 2019-08-12 2023-11-16 Deciphera Pharmaceuticals, Llc. Ripretinib for treating gastrointestinal stromal tumors
CN110606860B (zh) 2019-09-29 2021-12-10 上海勋和医药科技有限公司 一种吡啶磺酰胺磷酸酯类化合物、其制备方法及其用途
BR112022013109A2 (pt) 2019-12-30 2022-09-06 Deciphera Pharmaceuticals Llc Formulações de inibidor de quinase amorfo e métodos de uso das mesmas
JP2023509628A (ja) 2019-12-30 2023-03-09 デシフェラ・ファーマシューティカルズ，エルエルシー １－（４－ブロモ－５－（１－エチル－７－（メチルアミノ）－２－オキソ－１，２－ジヒドロ－１，６－ナフチリジン－３－イル）－２－フルオロフェニル）－３－フェニル尿素の組成物
WO2022192703A1 (en) * 2021-03-12 2022-09-15 Eil Therapeutics, Inc. Compounds having tetrahydroindolizine-1-carboxamide as bcl-2 inhibitors
WO2023057394A1 (en) 2021-10-04 2023-04-13 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2484209C (en) * 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
AU2003249713A1 (en) * 2002-07-03 2004-01-23 Axys Pharmaceuticals, Inc. 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis
GB0224557D0 (en) * 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
BRPI0620151A2 (pt) 2005-12-22 2010-06-29 Wyeth Corp composto; composição farmacêutica; método de tratar ou inibir o crescimento de células tumorais cancerosas em um mamìfero que deste necessita; método; e processo
US7902218B2 (en) * 2006-12-12 2011-03-08 Bristol-Myers Squibb Company Substituted tetrahydroisoquinolines as β-secretase inhibitors
MX2009011211A (es) * 2007-04-16 2009-10-30 Abbott Lab Indoles sustituidos en la posicion 7 inhibidores de mci-1.
PT2149560E (pt) * 2007-05-22 2015-07-13 Astellas Pharma Inc Composto de tetra-hidroisoquinolina substituído na posição 1
EP2252617A1 (en) * 2008-02-13 2010-11-24 CGI Pharmaceuticals, Inc. 6-aryl-imidaz0[l, 2-a]pyrazine derivatives, method of making, and method of use thereof
RU2525116C2 (ru) * 2008-12-19 2014-08-10 Дженентек, Инк. Гетероциклические соединения и способы применения
TWI520960B (zh) * 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
US20120301080A1 (en) 2011-05-23 2012-11-29 Senko Advanced Components, Inc. True one piece housing fiber optic adapter
CN104125954A (zh) 2011-12-23 2014-10-29 诺华股份有限公司 用于抑制bcl2与结合配偶体相互作用的化合物
WO2013096060A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
US9126980B2 (en) 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
JP2015503516A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
KR20140107575A (ko) 2011-12-23 2014-09-04 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
CN103177906A (zh) 2011-12-26 2013-06-26 西门子公司 用于中压开关设备的断路器
ITPR20110103A1 (it) 2011-12-27 2013-06-28 G E A F S R L Metodo e apparato per la sterilizzazione di una soluzione liquida mediante radio frequenza
US9114953B2 (en) 2011-12-29 2015-08-25 Inventio Ag Emergency operation of elevators based on an indicated emergency condition
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE212013000059U1 (de) 2012-01-24 2014-09-11 Danfoss Power Electronics A/S Entfeuchter

Also Published As

Publication number Publication date
UA119738C2 (uk) 2019-08-12
PT2829545T (pt) 2016-07-13
CL2014001865A1 (es) 2015-06-26
BR102014017997B1 (pt) 2020-05-19
ME02641B (me) 2017-06-20
CR20140336A (es) 2015-10-07
US20170143746A1 (en) 2017-05-25
JP2015028017A (ja) 2015-02-12
FR3008979B1 (fr) 2015-07-24
CN104341451A (zh) 2015-02-11
KR20170001694A (ko) 2017-01-04
UY35661A (es) 2015-02-27
ZA201405418B (en) 2020-02-26
EA201400754A3 (ru) 2015-03-31
WO2015011399A1 (fr) 2015-01-29
TN2014000301A1 (fr) 2015-12-21
MD4551C1 (ro) 2018-09-30
EP2829545A1 (fr) 2015-01-28
IL233580A0 (en) 2014-11-02
CU20140095A7 (es) 2016-02-29
EA027444B1 (ru) 2017-07-31
SA114350669B1 (ar) 2016-04-11
RU2617682C2 (ru) 2017-04-26
AR097008A1 (es) 2016-02-10
AU2014203808B2 (en) 2018-09-20
NZ627178A (en) 2016-01-29
ES2593417T3 (es) 2016-12-09
CA2856886A1 (fr) 2015-01-23
AP2014007773A0 (en) 2014-07-31
RS55098B1 (sr) 2016-12-30
HK1204623A1 (en) 2015-11-27
US20150031648A1 (en) 2015-01-29
AU2014203808A1 (en) 2015-02-12
SV2014004771A (es) 2015-01-28
DK2829545T3 (en) 2016-09-19
KR101713103B1 (ko) 2017-03-07
MA37213A1 (fr) 2016-06-30
PH12014000194A1 (en) 2015-06-29
MA37213B1 (fr) 2017-03-31
BR102014017997A2 (pt) 2015-11-17
SG10201403939WA (en) 2015-02-27
PL2829545T3 (pl) 2016-12-30
JO3160B1 (ar) 2017-09-20
NI201400080A (es) 2014-10-24
CA2856886C (fr) 2016-08-02
CN104341451B (zh) 2018-04-03
MD4551B1 (ro) 2018-02-28
TWI527824B (zh) 2016-04-01
TW201504254A (zh) 2015-02-01
ECSP14008757A (es) 2016-01-29
MD20140073A2 (en) 2015-01-31
MX351467B (es) 2017-10-17
MX2014008866A (es) 2015-07-21
HRP20161202T8 (hr) 2016-12-30
EP2829545B1 (fr) 2016-06-22
US9597341B2 (en) 2017-03-21
US9115159B2 (en) 2015-08-25
RU2014130129A (ru) 2016-02-10
CU24316B1 (es) 2018-02-08
HRP20161202T1 (hr) 2016-11-04
IL233580B (en) 2020-03-31
DOP2014000163A (es) 2015-01-15
PE20150218A1 (es) 2015-02-14
JP5894638B2 (ja) 2016-03-30
US20150313923A1 (en) 2015-11-05
KR20150011785A (ko) 2015-02-02
MY173258A (en) 2020-01-09
GEP201706704B (en) 2017-07-25
PH12014000194B1 (en) 2015-06-29
HUE029616T2 (en) 2017-03-28
FR3008979A1 (fr) 2015-01-30
EA201400754A2 (ru) 2014-12-30
SI2829545T1 (sl) 2016-10-28
HK1201536A1 (zh) 2015-09-04

Similar Documents

Publication Publication Date Title
CY1117834T1 (el) Νεα φωσφορικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν
CY1121804T1 (el) Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους
CY1118756T1 (el) Νεα παραγωγα πυρρολιου, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν
CY1118058T1 (el) Νεα παραγωγα θειενοπυριμιδινης, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1119387T1 (el) Τριαζολοπυραζινες ως αναστολεις brd4 για χρηση στην αντιμετωπιση καρκινου
CY1119762T1 (el) C-17-ετεροαρυλικα παραγωγα ελαιολικου οξεος και μεθοδοι χρησης αυτων
CY1115945T1 (el) Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση
MX2017004039A (es) Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso.
CY1119953T1 (el) Yποκατεστημενες πυριδοπυραζινες ως προτυποι syk ανοστολεις
CY1122870T1 (el) Νεα πιπεριδινυλ παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που τα περιεχουν
CY1119714T1 (el) Ενωσεις αναστολεων
MY198880A (en) Phosphoramidate nucleoside derivatives as anticancer agents
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
PH12016500643A1 (en) New octahydro - cyclobuta [1,2-c;3,4-c`] dipyrrol -2- yl
CY1120236T1 (el) Προφαρμακα αμινο-κιναζολινης αναστολεα κινασης
CO2017008600A2 (es) Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos
MX2015011779A (es) Nucleosidos biciclicos unidos en puente.
CY1120475T1 (el) Νεα παραγωγα ινδολιου και πυρρολιου, μεθοδος για την παρασκευη αυτωn και φαρμακευτικες συνθεσεις που περιεχουν αυτα
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
BR112015018504A2 (pt) moduladores de flap
CY1121273T1 (el) Παραγωγα 6-αλκυνυλο-πυριδινης ως smac μιμητικα
MX368767B (es) (5,6-dihidro)pirimido[4,5-e]indolizinas.
CY1122080T1 (el) 7-(μορφολινυλ)-2-(n-πιπεραζινυλ) μεθυλοθειαινο [2,3-c]πυριδινης ως αντικαρκινικα φαρμακα
CR20150456A (es) Sal abexinostate novedosos asociados en forma cristalina, procedimiento de preparación y composiciones farmacéuticas que los contienen